Noradrenaline (Norepinephrine) — A Comprehensive Reference

1. Chemistry & Classification

2. Biosynthesis Pathway

Catecholamine synthesis pathway — Neuroscience: Exploring the Brain, 5th Ed.

• End-product inhibition: rising cytosolic catecholamine levels suppress TH
• Ca²⁺ activation: during high-rate firing, elevated [Ca²⁺] accelerates TH, matching supply to demand
• Long-term demand: sustained stimulation upregulates TH mRNA

Source: Neuroscience: Exploring the Brain, 5th Ed., pp. 503–504; Eric Kandel: Principles of Neural Science, 6th Ed., p. 409

3. Sites of Synthesis and Release

Central Nervous System

• Locus coeruleus (LC): the primary noradrenergic nucleus, located in the pons. Though containing relatively few neurons, it projects broadly to the cortex, cerebellum, hippocampus, and spinal cord, modulating arousal, attention, stress response, and autonomic tone. — Kandel, Principles of Neural Science

Peripheral Nervous System

• Postganglionic sympathetic nerve terminals: NE is the principal neurotransmitter here, released onto effector organs (heart, vasculature, kidney, gut, etc.)
• Adrenal medulla: releases ~20% NE + ~80% epinephrine directly into the bloodstream as a hormonal response to systemic stress

4. Receptor Pharmacology and Downstream Signalling

1. β₁ agonist → Gs → adenylyl cyclase → cAMP ↑ → PKA activation
2. PKA phosphorylates L-type Ca²⁺ channels → greater Ca²⁺ entry
3. PKA phosphorylates troponin I → increased TnC efficacy
4. PKA phosphorylates phospholamban → faster SERCA2 activity → faster diastolic relaxation

5. Physiological Actions — System by System

Cardiovascular

Renal / Splanchnic

• At normal MAP: α₁ constriction reduces renal, hepatic, splanchnic, and skeletal muscle flow
• When MAP is profoundly reduced (shock): NE restores perfusion pressure, increasing urine output and GFR
• Prolonged high-dose NE risks sustained renal and mesenteric ischaemia — a major limitation

Pulmonary

• Stimulates α₁ in pulmonary arteries → dose-related ↑ pulmonary arterial pressure → risk of RV dysfunction at high doses in patients with pulmonary hypertension

CNS (physiological)

• Locus coeruleus firing increases arousal, attention, and "fight-or-flight" readiness
• Amygdala activates LC during acute stress → high NE impairs prefrontal cognition while sharpening reactive responses

6. Metabolism and Elimination

1. Uptake-1 (neuronal reuptake) via the norepinephrine transporter (NET) — primary mechanism at the synapse
2. Enzymatic degradation:
   • MAO (monoamine oxidase, mitochondrial) → deamination
   • COMT (catechol-O-methyltransferase, cytosolic) → methylation
   • Final metabolite: vanillylmandelic acid (VMA) — measured in 24-h urine for pheochromocytoma diagnosis

7. Why Noradrenaline is the First-Line Emergency Vasopressor

The Core Rationale

• Powerful α₁ vasoconstriction → rapidly restores MAP in vasodilated/distributive shock
• Adequate β₁ inotropism → maintains/improves cardiac output without solely increasing afterload
• No meaningful β₂ activity → avoids peripheral vasodilation that would worsen hypotension
• Lower arrhythmia risk than dopamine or epinephrine — clinically significant advantage
• Baroreceptor-mediated bradycardia prevention → heart is protected from tachyarrhythmias

"The preferred vasopressor for distributive shock is norepinephrine, because it is a strong vasoconstrictor with enough beta-adrenergic effects to increase myocardial contractility and to protect the heart against the increased afterload posed by vasoconstriction." — Goldman-Cecil Medicine, International Edition

Evidence Over Dopamine

• Fewer adverse events, particularly arrhythmias, with NE
• Dopamine was associated with higher mortality in cardiogenic shock
• Meta-analysis confirmed NE superior to dopamine in in-hospital and 28-day mortality
• NE increases GFR and urine output equally to dopamine in septic patients, but without dopamine's side effects

8. Clinical Indications — Where and When to Use

Primary Indications

Specific Contexts

• First-line when MAP <65 mmHg despite fluid resuscitation (≥30 mL/kg crystalloid)
• Goal MAP 65 mmHg (equivalent outcomes to 80–85 mmHg target; higher target does NOT improve mortality and increases adverse events)
• NE preferred over: dopamine (more arrhythmias), phenylephrine (no β₁ support), vasopressin alone (not a first-line sole agent)

• NE + methylene blue (nitric oxide scavenger) or hydroxocobalamin for severe cases refractory to NE alone

• Anaphylaxis: epinephrine remains first-line (β₂ bronchodilation is needed)
• Cardiac arrest: epinephrine first-line (α₁ + β₁)
• Isolated bradycardia: atropine / pacing

9. Dosing and Administration Protocols

Dosing (Adult)

• Start 0.05–0.1 μg/kg/min; titrate up
• Fluid-refractory shock → add NE or epinephrine

Route of Administration

• Central venous catheter (CVC) preferred — to prevent tissue necrosis from extravasation
• Peripheral IV is acceptable for short durations in dilute solutions (≤20 μg/mL) via antecubital or larger peripheral veins with close monitoring — a large retrospective observational study supports this when CVC insertion would cause unacceptable delay (Barash, Clinical Anesthesia 9e, p. 963)

Preparation

• Standard concentration: 4 mg in 250 mL D5W or NS = 16 μg/mL
• High concentration (fluid-restricted): 16 mg in 250 mL = 64 μg/mL

10. Emergency Protocol — Step-by-Step (Septic Shock)

SEPTIC SHOCK VASOPRESSOR PROTOCOL
════════════════════════════════════════════════════
STEP 1: Fluid Resuscitation
  • 30 mL/kg IV crystalloid (lactated Ringer preferred) over ≤3 hours
  • Reassess MAP, lactate, urine output, mental status

STEP 2: If MAP <65 mmHg despite fluids
  → START Norepinephrine
  • Dose: 3–5 μg/min IV (central line preferred)
  • Titrate every 5–15 min to MAP ≥65 mmHg
  • Maximum: ~50 μg/min before adding second agent

STEP 3: If MAP target not achieved on NE alone
  → ADD Vasopressin 0.03 units/min (fixed dose, do not titrate)
    Purpose: NE-sparing, may reduce catecholamine dose
    OR
  → ADD Epinephrine 1–15 μg/min if cardiac output depressed

STEP 4: If myocardial dysfunction present (echo evidence)
  → ADD Dobutamine 2–15 μg/kg/min
    (do NOT substitute for NE — add on top)

STEP 5: Refractory vasodilatory shock
  → Consider Angiotensin II 20 ng/kg/min (titrate to 200 ng/kg/min)
    Adrenergic-sparing effect; does not reduce mortality but reduces NE requirements

STEP 6: Ongoing monitoring
  • MAP target: 65 mmHg (unless prior hypertension → target 75 mmHg)
  • CVP target: 8–12 mmHg (on mechanical ventilation: 12–15 mmHg)
  • Lactate clearance: target >10% per 2 hours
  • Urine output: >0.5 mL/kg/hr
  • Wean NE as haemodynamics and source control improve
════════════════════════════════════════════════════

11. Adverse Effects and Contraindications

• Hypovolaemia — must correct volume first; NE on empty tank worsens microvascular ischaemia
• Coronary artery disease with flow-limiting stenoses — NE increases MVO₂; may precipitate myocardial ischaemia or graft spasm (internal mammary / radial artery grafts)
• Severe pulmonary hypertension — use with inhaled pulmonary vasodilator
• Halothane anaesthesia — risk of sensitised arrhythmias (historical, largely obsolete)

12. Noradrenaline vs Other Vasopressors — At a Glance

13. Recent Evidence (2024–2026)

1. Ahn et al., Chest 2024 [PMID 38972348] — Systematic review/meta-analysis comparing early vs late NE initiation in septic shock: early initiation reduces time to MAP target and may improve outcomes.
2. Kotani et al., Crit Care 2024 [PMID 39736782] — Meta-analysis of non-adrenergic vasopressors (vasopressin, angiotensin II) vs NE in vasodilatory shock: non-adrenergic agents are useful adjuncts but do not replace NE as the anchor agent.
3. Shi et al., Crit Care 2025 [PMID 40329359] — Updated meta-analysis with trial sequential analysis: early NE significantly lowers 28-day mortality and time to shock reversal in septic shock patients.

⚠️ Current evidence update: The 2025 meta-analysis by Shi et al. supports initiating NE early — concurrently with fluid resuscitation rather than waiting for full 30 mL/kg fluid challenge — in patients with obvious vasodilatory shock, potentially reducing mortality.

Summary